Literature DB >> 27557553

Development of a multisystem surveillance database for transfusion-transmitted infections among blood donors in the United States.

Roger Y Dodd1, Edward P Notari1, Diane Nelson1, Gregory A Foster2, David E Krysztof2, Zhanna Kaidarova3, Lisa Milan-Benson4, Debra A Kessler4, Beth H Shaz4, Farnaz Vahidnia3, Brian Custer3,5, Susan L Stramer2.   

Abstract

BACKGROUND: The frequency of positive test results for transfusion-transmitted infections (TTIs) among blood donors is an important index of safety; thus, appropriate monitoring is critical, particularly when there are changes in policies affecting donor suitability. STUDY DESIGN AND METHODS: Testing algorithms from three large blood systems were reviewed and consensus definitions for a surveillance-positive result for hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human T-cell lymphotropic virus (HTLV) established. In addition, information on each donation, including donor demographics and location, was collected. Combined data were analyzed to characterize the epidemiology of TTIs by person, place, and time.
RESULTS: Data from 14.8 million donations were collected for 2011 to 2012, representing more than 50% of the US blood supply. Surveillance-positive rates per 10,000 donations were as follows: HBV, 0.76; HCV, 2.0; HIV, 0.28; and HTLV 0.34. Rates did not vary between the 2 years, although there was variation within a year. With the exception of HTLV, rates were higher among males, and all rates were higher among first-time donations. Window-period donations (those positive only in nucleic acid tests) were infrequent (HBV, 13; HCV, 60; HIV, 14) during the 2-year period. Frequencies of surveillance-positive results varied by donor age and residence location.
CONCLUSIONS: We demonstrated that standardized data from multiple major US blood systems can be combined and analyzed for change. However, TTI frequencies are low, impacting their sensitivity to change. Furthermore, observed fluctuations in TTI frequencies may be secondary to changes in blood donor demographics rather than necessarily reflecting the immediate impact of policy modification.
© 2016 AABB.

Entities:  

Mesh:

Year:  2016        PMID: 27557553     DOI: 10.1111/trf.13759

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Recent and occult hepatitis B virus infections among blood donors in the United States.

Authors:  Sumathi Ramachandran; Jamel A Groves; Guo-Liang Xia; Paula Saá; Edward P Notari; Jan Drobeniuc; Amanda Poe; Natasha Khudyakov; Sarah F Schillie; Trudy V Murphy; Saleem Kamili; Chong-Gee Teo; Roger Y Dodd; Yury E Khudyakov; Susan L Stramer
Journal:  Transfusion       Date:  2018-11-30       Impact factor: 3.157

2.  Probable transmission of hepatitis E virus (HEV) via transfusion in the United States.

Authors:  John R Ticehurst; Nora Pisanic; Michael S Forman; Carly Ordak; Christopher D Heaney; Edgar Ong; Jeffrey M Linnen; Paul M Ness; Nan Guo; Hua Shan; Kenrad E Nelson
Journal:  Transfusion       Date:  2019-01-31       Impact factor: 3.157

3.  Attitudes, perceptions and knowledge among men who have sex with men towards the blood donation deferral policy in Israel.

Authors:  Itzchak Levy; Liraz Olmer; Yuval Livnat; Adir Yanko; Eilat Shinar
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

4.  Prevalence and trends in transfusion-transmissible infections among blood donors in Brazil from 2010 to 2016.

Authors:  Lívia Lara Pessoni; Érika Carvalho de Aquino; Keila Correia de Alcântara
Journal:  Hematol Transfus Cell Ther       Date:  2019-07-04

5.  Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.

Authors:  Shelley N Facente; Eduard Grebe; Katie Burk; Meghan D Morris; Edward L Murphy; Ali Mirzazadeh; Aaron A Smith; Melissa A Sanchez; Jennifer L Evans; Amy Nishimura; Henry F Raymond
Journal:  PLoS One       Date:  2018-04-11       Impact factor: 3.240

6.  Revisiting human T-cell lymphotropic virus types 1 and 2 infections among rural population in Gabon, central Africa thirty years after the first analysis.

Authors:  Melanie Caron; Guillaume Besson; Cindy Padilla; Maria Makuwa; Dieudonne Nkoghe; Eric Leroy; Mirdad Kazanji
Journal:  PLoS Negl Trop Dis       Date:  2018-10-25

7.  Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment.

Authors:  Shawn D Keil; Izabela Ragan; Susan Yonemura; Lindsay Hartson; Nicole K Dart; Richard Bowen
Journal:  Vox Sang       Date:  2020-05-14       Impact factor: 2.996

8.  Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.

Authors:  Evan M Bloch; Ruchika Goel; Silvano Wendel; Thierry Burnouf; Arwa Z Al-Riyami; Ai Leen Ang; Vincenzo DeAngelis; Larry J Dumont; Kevin Land; Cheuk-Kwong Lee; Adaeze Oreh; Gopal Patidar; Steven L Spitalnik; Marion Vermeulen; Salwa Hindawi; Karin Van den Berg; Pierre Tiberghien; Hans Vrielink; Pampee Young; Dana Devine; Cynthia So-Osman
Journal:  Vox Sang       Date:  2020-07-20       Impact factor: 2.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.